Developping gene therapies and innovative treatments for nerve-related diseases
Notre mission
Nervosave Therapeutics develops a platform of local gene therapies that slow, stop and reverse a broad range of diseases involving peripheral nerves.
Our first aim is to develop best in class gene therapy for Charcot-Marie-Tooth (CMT) disease 1A and beyond for all CMT diseases.
Our platform has game-changing potential in several devastating diseases with clear therapeutic needs such as neuralgias, diabetic peripheral neuropathy and other degenerative diseases involving nerves.
We are Laureate
of the
Boost Invest MedVallée 2024
of the
Boost Invest MedVallée 2024